Management of the patient with drug-induced liver disease

Drug-Induced Liver Disease, Second Edition

Volumn , Issue , 2007, Pages 345-352

  Boyer, Thomas D ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955333636     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (40)

1. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22:145-55.
2. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French populationbased study. Hepatology 2002; 36:451-5.
3. Duh M-S, Walker AM, Kronlund KH. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiol Drug Saf 1999; 8:275-83.
4. Lemozit JP, Petit de la Rhodiere G, Lapeyre-Mestre M, et al. A comparative study of adverse drug reactions reported through hospital and private medicine. Br J Clin Pharmacol 1966; 41:166-8.
5. Maria V, Victorino R. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26:664-9.
6. Zimmermann HJ. Hepatic injury from the treatment of infectious and parasitic diseases. In: Zimmerman HJ, ed. Hepatotoxicity. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1999:613-9.
7. Brown SJ, Desmond RV. Hepatotoxicity of antimicrobial agents. Semin Liver Dis 2002; 22:157-67.
8. Tolman KG. The liver and lovastatin. Am J Cardiol 2002; 890:1374-80.
9. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126:1287-92.
10. Boyer TD, Sun N, Reynolds TB. Allopurinol hypersensitivity vasculitis and liver damage. West J Med 1977; 126:143-7.
11. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9:679-85.
12. Larrey D, Vial T, Miclaeff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination:report of 15 cases. Gut 1992; 33:368-71.
13. Zimmermann HJ. Anesthetic agents. In: Zimmerman HJ, ed. Hepatotoxicity. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1999:457-82.
14. Varma RR, Whitesell RC, Iskandarani MM. Halothane hepatitis without halothane: role of inapparent circuit contamination and its prevention. Hepatology 1985; 5:1159-62.
15. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354:731-9.
16. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002; 22:137-44.
17. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474-85.
18. Spielberg SP, Gordon GB, Blake DA, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981; 305:722-7.
19. Christ DD, Satoh H, Kenna JG, et al. Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane. Drug Metab Dispos 1988; 16:135-40.
20. Njoku D, Laster MJ, Gong DH, et al. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1977; 84:173-8.
21. Sigurdsson AB, Hreidarsson AB, Thiodleifsson B. Enflurane hepatitis. A report of a case with a previous history of halothane hepatitis. Acta Anaesthesiol Scand 1985; 29:495-6.
22. Lewis JH, Zimmerman HJ, Ishak KG, et al. Enflurane hepatotoxicity. A clinicopathologic study of 24 cases. Ann Intern Med 1983; 98:984-92.
23. Zimmermann HF. Psychotropic and anticonvulsant agents. In: Zimmerman HJ, ed. Hepatotoxicity. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1999:483-516.
24. Konig SA, Schenk M, Sick C, et al. Fatal liver failure associated with valproate therapy in a patient with Friedreich’s disease: review of valproate hepatotoxicity in adults. Epilepsia 1999; 40:1036-40.
25. Maddrey WC. Drug-induced hepatotoxicity. J Clin Gastroenterol 2005; 39:S83-9.
26. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000; 132:118-21.
27. Menees SB, Anderson MA, Chensue SW, et al. Hepatic injury in a patient taking rosiglitazone. J Clin Gastroenterol 2005; 39:638-40.
28. Scheen AJ. Hepatotoxicity with thiazolidinediones. Is it a class effect? Drug Saf 2001; 24:873-88.
29. Bonkovsky HL, Azar R, Bird S, et al. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci 2002; 47:1632-7.
30. Schiodt FV, Rochling FA, Casey DL, et al. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997; 337:1112-7.
31. Prendergast KA, Berg CL, Wisniewski R. Troglitazone-associated hepatotoxicity teated successfully with steroids. Ann Intern Med 2000; 133:751.
32. Sharp JR, Ishak KG, Zimmerman HF. Chronic active hepatitis and severe heaptic necrosis associated with nitrofurantoin. Ann Intern Med 1980; 92:14-9.
33. Rodman JS, Deutsch DJ, Gutman SI. Methyldopa hepatitis: a report of six cases and review of the literature. Am J Med 1976; 60:941-8.
34. Ajit C, Suvannasankha A, Zaeri N, et al. Tebinafine-associated hepatotoxicity. Am J Med Sci 2003; 325:292-5.
35. Agca E, Akcay A, Simsek H. Ursodeoxycholic acid for terbinafine-induced toxic hepatitis. Ann Pharmacol 2004; 38:1088-9.
36. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50:436-9.
37. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42:481-9.
38. Barshes NR, Lee TC, Balkrishnam R, et al. Risk stratification of adult patients undergoing orthotopic liver transplantation for fulminant hepatic failure. Transplantation 2006; 81:195-201.
39. Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003; 23:217-26.
40. Sanyal AJ, Stravitz RT. Acute liver failure. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease. 4th ed. Philadelphia, PA: W.B. Saunders, 2003:445-96.